Drug Trial Radar · NCT07614984
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Oct 12, 2027
Study completion Oct 12, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C). The goals of this trial are to evaluate: * if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood * if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood * the safety and tolerability of taking MK-7262 and enlicitide alone and together
Conditions
- Lipoprotein(a)
Interventions
MK-7262Drug
Oral Coated Tablet
EnlicitideDrug
Oral Coated Tablet
Placebo for MK-7262Drug
Oral Coated Tablet
Placebo for enlicitideDrug
Oral Coated Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8Time frame: Baseline and Week 8
- Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8Time frame: Baseline and Week 8
- Number of Participants who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 20 Weeks
- Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 12 Weeks
Locations
77 sites in 9 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular - Alexander City ( Site 0158)
Alexander City, Alabama · Recruiting
AMR Clinical Mobile ( Site 0149)
Mobile, Alabama · Recruiting
National Heart Institute ( Site 0113)
Beverly Hills, California · Recruiting
Headlands Research CTR Lincoln ( Site 0127)
Lincoln, California · Recruiting
Chase Medical Research, LLC ( Site 0163)
Waterbury, Connecticut · Recruiting
Soffer Health Institute ( Site 0123)
Hollywood, Florida · Recruiting
Westside Center for Clinical Research ( Site 0161)
Jacksonville, Florida · Recruiting
Inpatient Research Clinic ( Site 0110)
Miami Lakes, Florida · Recruiting
Clinical Research Trials of Florida ( Site 0101)
Tampa, Florida · Recruiting
Conquest Research LLC ( Site 0140)
Winter Park, Florida · Recruiting
Flourish Research - Bowie ( Site 0106)
Bowie, Maryland · Recruiting
Velocity Clinical Research Rockville ( Site 0146)
Rockville, Maryland · Recruiting
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0132)
Troy, Michigan · Recruiting
Minneapolis Heart Institute - Minneapolis ( Site 0130)
Minneapolis, Minnesota · Recruiting
Montana Medical Research, Inc. ( Site 0156)
Missoula, Montana · Recruiting
New Mexico Clinical Research & Osteoporosis Center ( Site 0119)
Albuquerque, New Mexico · Recruiting
Laurelton Heart Specialist PC ( Site 0155)
Rosedale, New York · Recruiting
Velocity Clinical Research, Durham ( Site 0145)
Durham, North Carolina · Recruiting
Remington-Davis, Inc. ( Site 0107)
Columbus, Ohio · Recruiting
Holston Medical Group ( Site 0117)
Kingsport, Tennessee · Recruiting
Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0154)
Houston, Texas · Recruiting
DM Clinical Research ( Site 0115)
Tomball, Texas · Recruiting
Carient Heart & Vascular - Manassas ( Site 0165)
Manassas, Virginia · Recruiting
Rainier Clinical Research Center ( Site 0116)
Renton, Washington · Recruiting
North York Diagnostic and Cardiac Centre ( Site 0203)
North York, Ontario, Canada · Recruiting
Ecogene-21 ( Site 0202)
Chicoutimi, Quebec, Canada · Recruiting
Clinique des Maladies Lipidiques de Quebec ( Site 0201)
Québec, Quebec, Canada · Recruiting
Diex Recherche Trois-Rivieres ( Site 0204)
Trois-Rivières, Quebec, Canada · Recruiting
Salud SURA Industriales ( Site 0405)
Medellín, Antioquia, Colombia · Recruiting
Clinica de la Costa S.A.S ( Site 0404)
Barranquilla, Atlántico, Colombia · Recruiting
Solano & Terront Servicios Medicos - UNIENDO SAS ( Site 0402)
Bogota, Cundinamarca, Colombia · Recruiting
IMAT S.A.S ( Site 0400)
Montería, Departamento de Córdoba, Colombia · Recruiting
Regionshospitalet Viborg ( Site 0507)
Viborg, Central Jutland, Denmark · Recruiting
Sanos Clinic - Nordjylland ( Site 0502)
Gandrup, North Denmark, Denmark · Recruiting
Esbjerg sygehus, Syddansk Universitetshospital ( Site 0505)
Esbjerg, Region Syddanmark, Denmark · Recruiting
OUH Svendborg Sygehus ( Site 0500)
Svendborg, Region Syddanmark, Denmark · Recruiting
zibp GmbH ( Site 0716)
Berlin, Germany · Recruiting
FutureMeds GmbH ( Site 0718)
Berlin, Germany · Recruiting
Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 0714)
Berlin, Germany · Recruiting
Klinikum Konstanz ( Site 0723)
Konstanz, Baden-Wurttemberg, Germany · Recruiting
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.